Key features and details
- Rabbit polyclonal to TRIP13/PCH2
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-TRIP13/PCH2 antibody
See all TRIP13/PCH2 primary antibodies
DescriptionRabbit polyclonal to TRIP13/PCH2
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Predicted to work with: Rat, Pig, Chimpanzee, Gorilla, Orangutan, Elephant
Synthetic peptide corresponding to Human TRIP13/PCH2 aa 50-100.
Database link: NP_004228.1
- HeLa, 293T and Jurkat whole cell lysate (ab7899)
This product was previously labelled as TRIP13
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: 99% Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab128171 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 49 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
Sequence similaritiesBelongs to the AAA ATPase family.
- Information by UniProt
- 16E1-BP antibody
- 16E1BP antibody
- Homo sapiens HPV16 E1 protein binding protein mRNA complete cds antibody
All lanes : Anti-TRIP13/PCH2 antibody (ab128171) at 0.1 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : 293T whole cell lysate at 50 µg
Lane 4 : Jurkat whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 49 kDa
Exposure time: 3 minutes
Detection of TRIP13/PCH2 by Western Blot of Immunprecipitate.
a128171, at 1 µg/ml, staining TRIP13/PCH2 in HeLa whole cell lysate immunoprecipitated using ab128171 at 6 µg/mg lysate (1 mg/IP; 20% of IP loaded/lane).
Lane 2: Control IgG.
Detection: Chemiluminescence with exposure time of 10 seconds.
ab128171 has been referenced in 2 publications.
- Zhu MX et al. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp Clin Cancer Res 38:409 (2019). PubMed: 31533816
- Yost S et al. Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. Nat Genet 49:1148-1151 (2017). WB ; Human . PubMed: 28553959